


KIRA6

Cat. No.:	HY-19708		
CAS No.:	1589527-65-0		
Molecular Formula:	C ₂₈ H ₂₅ F ₃ N ₆ O		
Molecular Weight:	518.53		
Target:	IRE1		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (48.21 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	1.9285 mL	9.6426 mL	19.2853 mL
	5 mM	0.3857 mL	1.9285 mL	3.8571 mL
	10 mM	0.1929 mL	0.9643 mL	1.9285 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.5 mg/mL (0.96 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.5 mg/mL (0.96 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.5 mg/mL (0.96 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	KIRA6 is an advanced small-molecule IRE1α RNase kinase inhibitor with an IC ₅₀ of 0.6 μM ^[2] . KIRA6 can trigger an apoptotic response ^[1] .
IC₅₀ & Target	IC ₅₀ : 0.6 μM (IRE1α RNase kinase) ^[2]
In Vitro	KIRA6 (1nM-100μM) binds to the cytoplasmic domain of KIT with a K _d value of 10.8 μM ^[1] . KIRA6 (10-1000 nM; 72 hours) strongly compromises the viability of the KIT-dependent cell line HMC-1.1 at the low nM

concentration, in a manner that coincided with KIT blockade^[1].

KIRA6 (10-1000 nM; 1 hour) reduces signaling output of KIT, including the phosphorylation of KIT as well as its downstream signaling modules, PSTAT5 and phosphorylated ERK1/2^[1].

KIRA6 (1 μ M; 0-48 hours) inhibits Ins1 mRNA decay from IRE1 α hyperactivation at a dose-dependent manner^[2].

KIRA6 (0.1-10 μ M; 72 hours) dose-dependently reduces 1NM-PP1 potentiation of Ins1 apoptosis during ER stress in a dose-dependent manner^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HMC-1.1 cells
Concentration:	10 nM, 30 nM, 100 nM, 300 nM, 1000 nM
Incubation Time:	72 hours
Result:	Inhibited cell viability from 30 nM.

Western Blot Analysis^[1]

Cell Line:	HMC-1.1 cells
Concentration:	10 nM, 30 nM, 100 nM, 300 nM, 1000 nM
Incubation Time:	1 hours
Result:	Reduced expression of phosphorylated KIT, STAT5 and ERK1/2.

RT-PCR^[2]

Cell Line:	INS-1 IRE1 α (WT) cells
Concentration:	1 μ M
Incubation Time:	0 hour, 12 hours, 24 hours, 48 hours
Result:	Inhibited Ins1 mRNA expression.

Apoptosis Analysis^[2]

Cell Line:	INS-1 IRE1 α (WT) cells
Concentration:	1-10 μ M
Incubation Time:	72 hours
Result:	Reduced 1NM-PP1 potentiation of Ins1 apoptosis during ER stress.

In Vivo

KIRA6 (intraperitoneal injection; 5 mg/kg; 37 days) shows significant amelioration of random glucose levels over several weeks compared to vehicle, both fed ad lib^[2].

KIRA6 (intraperitoneal injection; 5 mg/kg; 21 or 18 days postinjections) increases both plasma insulin and C-peptide levels, remains insulin-positive islet areas at high level after stopping injections in the Akita Mouse^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Ins2+/Akita mice ^[2]
Dosage:	5 mg/kg

Administration:	Intraperitoneal injection; 5 mg/kg; 21 or 18 days postinjections
Result:	Attenuates b cell functional loss, increased insulin levels.

CUSTOMER VALIDATION

- Science. 2019 Jul 19;365(6450):eaau6499.
- ACS Cent Sci. 2020 Jan 22;6(1):76-82.
- Nano Today. April 2022, 101416.
- ACS Nano. 2021 Aug 20.
- Nat Commun. 2024 Jan 2;15(1):72.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Mahameed M, et al. The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors. Cell Death Dis. 2019 Apr 1;10(4):300.
- [2]. Ghosh R, et al. Allosteric inhibition of the IRE1 α RNase preserves cell viability and function during endoplasmic reticulum stress. Cell. 2014 Jul 31;158(3):534-48.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA